Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Phase 1a Primary Objectives 1. To determine the maximum tolerated dose (MTD) of PF-03084014 when administered twice daily for 21 days alone in patients with advanced malignancies (encompassing advanced solid tumors and relapsed or refractory T-ALL/LBL). Phase 1b Primary Objectives 1. To determine the MTD of PF-03084014 when administered twice daily for 21 days in combination with dexamethasone given once daily on Day 1 to Day 3 and Day 11 to Day 13 of each cycle in patients with advanced malignancies (encompassing advanced solid tumors and relapsed or refractory T-ALL/LBL).
Critère d'inclusion
- advanced solid tumor malignancies or relapsed or refractory acute T-cell lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL)